Ironwood prices stock offering

Ironwood Pharmaceuticals Inc., looking to prepare for the launch of a drug to treat irritable bowel syndrome with constipation, announced the pricing of an underwritten public offering of 5.25 million shares of its Class A common stock at a price of $15.09 per share.

All shares are being offered by Ironwood, and the gross proceeds are expected to be $79.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Ironwood, the company said in a press release.


The company said it intends to use the net proceeds from this offering for general corporate purposes, including to further strengthen its balance sheet in advance of the potential market launch of linaclotide. Linaclotide is an investigational drug for the treatment of irritable bowel syndrome with constipation and chronic constipation. The drug candidate still requires regulatory approval.

J.P. Morgan Securities LLC and BofA Merrill Lynch are acting as joint active bookrunning managers, and Morgan Stanley & Co. LLC is acting as passive bookrunning manager of the offering. Ladenburg Thalmann & Co., Inc. is acting as a co-manager of the offering.

The offering is expected to close Feb. 15.

Chris Reidy can be reached at
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of